(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 April 2005 (21.04.2005)

PCT

(10) International Publication Number
WO 2005/035525 A3

(51) International Patent Classification[7]: C07D 403/12, A61K 31/497, C07K 5/10, A61P 31/14, C07D 401/14, 403/14, A61K 31/501, C07D 401/12, A61K 31/506, 31/4178, 31/517, 31/4439

(21) International Application Number:
PCT/US2004/029093

(22) International Filing Date:
7 September 2004 (07.09.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/500,670 5 September 2003 (05.09.2003) US

(71) Applicant *(for all designated States except US)*: **VERTEX PHARMACEUTICALS INCORPORATED** [US/US]; 130 Waverly Street, Cambridge, MA 02139-4242 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **PERNI, Robert, B.** [US/US]; 130 Robert Road, Marlborough, MA 01752 (US). **COURT, John, J.** [US/US]; 27 Ernies Drive, Littleton, MA 01460 (US). **BRITT, Shawn, D.** [US/US]; 56 Marilyn Road, Andover, MA 01810 (US). **PITLIK, Janos** [HU/US]; 1 Robin Circle, Westborough, MA 01581 (US). **VAN DRIE, John, H.** [US/US]; 34 Stinson Road, Andover, MA 01810 (US).

(74) Agent: **HALEY, James, F., Jr.**; Fish & Neave IP Group of Ropes & Gray LLP, 1251 Avenue of the Americas, New York, NY 10020 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*


(88) Date of publication of the international search report:
20 October 2005

(48) Date of publication of this corrected version:
19 January 2006


(15) Information about Correction:
see PCT Gazette No. 03/2006 of 19 January 2006, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: 2-AMIDO-4-ARYLOXY-1-CARBONYLPYRROLIDINE DERIVATIVES AS INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE



I-A



I-B

(57) Abstract: The present invention relates to compounds of formula I-A and I-B that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.

WO 2005/035525 A3